投资者增加了临床开发公司Medpace Holdings的股份, Investors boost stakes in Medpace Holdings, a clinical development firm, despite a "Hold" rating.

蒸发资本伙伴和Russell投资集团在第四季度增加了对Medpace控股公司的股份,Medpache控股公司是临床发展服务的提供者。 Distillate Capital Partners and Russell Investments Group increased their stakes in Medpace Holdings, a provider of clinical development services, in the fourth quarter. Russell的股份增加了50.6% 蒸馏厂的股份又增加了1 155股 Russell's stake rose by 50.6%, and Distillate's by an additional 1,155 shares. Medpace的股票开放量为297.72美元,市场上限为90亿美元。 Medpace's stock opened at $297.72, with a $9 billion market cap. 该公司的EPS为3.67美元,超过估计数,尽管它的“稳住”评级是361.90美元,目标价格是361.90美元。 The firm's EPS of $3.67 surpassed estimates, though it has a "Hold" rating with a target price of $361.90.